tiprankstipranks
Trending News
More News >
Atomera (ATOM)
NASDAQ:ATOM
US Market

Atomera (ATOM) AI Stock Analysis

Compare
636 Followers

Top Page

ATOM

Atomera

(NASDAQ:ATOM)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 5.2)
Rating:55Neutral
Price Target:
$5.00
▼(-4.58% Downside)
Action:ReiteratedDate:02/25/26
The score is held back primarily by weak financial performance (minimal revenue, deep losses, and ongoing cash burn), partially offset by strong technical price momentum and constructive but still early-stage commercialization commentary from the earnings call. Valuation provides limited support given the company’s loss-making profile and lack of dividend.
Positive Factors
Breakthrough GAA technical validation
Definitive GAA silicon results demonstrate MST’s technical compatibility with leading advanced-node transistor architectures, creating a durable competitive edge. Success in GAA increases addressable market (TSMC, Samsung, Intel) and shortens path from evaluation to licensing if customers confirm performance in their process flows.
Strategic equipment OEM partnership
A formal OEM partnership reduces adoption friction by integrating MST validation into customer tooling and supply chains. OEM endorsement helps scale customer trials, improves credibility with foundries/IDMs, and materially raises the probability that MST becomes an incorporated process step across multiple manufacturers.
Registered direct offering strengthens runway
A $25M registered direct offering meaningfully bolsters near-term liquidity and extends the company’s runway, reducing immediate financing pressure. Improved cash resources allow sustained R&D, wafer runs, and customer qualification cycles critical to converting technical wins into recurring license and royalty revenues.
Negative Factors
Extremely low current revenue base
Revenue is effectively immaterial relative to cost structure, indicating commercialization remains nascent. Low current receipts mean the business depends on converting lengthy qualification cycles into licensing or royalties; until then, operating losses will persist and scaling economics remain unproven.
Persistent cash burn and declining cash balance
Sustained negative operating cash flows materially shorten runway absent further financing. Persistent cash burn forces management to prioritize funding over growth, increases dilution risk, and constrains the company’s ability to finance the multiple 6–9 month customer qualification cycles needed to generate durable licensing revenue.
Ongoing net losses, dilution and capital erosion
Large recurring losses erode equity and have required dilutive financings, which dilute shareholders and can signal recurring funding needs. Continued reliance on equity to fund operations highlights weak internal cash generation and elevates execution risk if commercial milestones are delayed or fail to scale.

Atomera (ATOM) vs. SPDR S&P 500 ETF (SPY)

Atomera Business Overview & Revenue Model

Company DescriptionAtomera Incorporated develops, commercializes, and licenses proprietary materials, processes, and technologies for the semiconductor industry in North America and the Asia Pacific. The company's lead technology is the Mears Silicon Technology, a thin film of reengineered silicon that can be applied as a transistor channel enhancement to CMOS-type transistors. Its customers include foundries, integrated device manufacturers, fabless semiconductor manufacturers, original equipment manufacturers, and electronic design automation companies. The company was formerly known as Mears Technologies, Inc. and changed its name to Atomera Incorporated in January 2016. Atomera Incorporated was incorporated in 2001 and is headquartered in Los Gatos, California.
How the Company Makes MoneyAtomera generates revenue primarily through licensing its MST technology to semiconductor manufacturers. The company charges fees for the license agreements that allow clients to integrate Atomera's technology into their production processes. Additionally, Atomera may earn revenue from research and development contracts, collaborations with industry partners, and potential royalties based on the sales of products that utilize MST. Key partnerships with major semiconductor firms are crucial, as they not only provide direct revenue but also validate Atomera's technology, leading to wider adoption and increased sales opportunities.

Atomera Earnings Call Summary

Earnings Call Date:Feb 12, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Neutral
The call highlighted substantial and potentially high-value technical progress across multiple high-growth semiconductor markets—most notably definitive GAA silicon results, active wafer runs, a commercial GaN customer and a strategic OEM partnership. However, these technical advancements have yet to translate into meaningful revenue; the company remains pre-revenue on a commercial scale, reported ongoing net losses, experienced a material cash decline in 2025, and relied on dilutive equity financings. Commercial adoption timelines remain uncertain (6–9 month test cycles and customer validation), and 2026 expense accretion tied to bonus accruals will require achieving aggressive milestones. Overall, the technical momentum is strong but balanced by near-term financial and execution risks.
Q4-2025 Updates
Positive Updates
Breakthrough Gate-All-Around (GAA) Results
Obtained silicon results showing MST can be deposited into nanosheet GAA structures and delivers superior diffusion blocking versus currently used silicon arsenic; company expects customer evaluations and potential implementations with leading GAA customers (TSMC, Samsung, Intel and a new Japanese manufacturer) over the next few quarters.
Advancement of Multiple Target Markets
Progress reported across DRAM (wafer-based offerings with promising preliminary results pending final data in ~1 month), RF-SOI (wafer-based solutions targeting RF switch and LNA markets), power devices (TrenchFET, HBT) and GaN (first commercial customer running GaN-on-silicon wafers with MST).
GaN and Government-Funded Development
GaN-on-silicon concept paper approved to proposal stage for a Power America project, marking the company's first external development funding application and yielding multiple letters of support from potential customers and partners.
Record Wafer Runs and Increased Customer Engagement
Kicked off a record number of wafer runs in 2025 with multiple customers; many runs sent to customers' fabs and final customer test cycles expected to take 6-9 months—setting up potential joint development agreements and licensing opportunities.
R&D Investment and Improved Development Efficiency
R&D increased to $10.2M in 2025 (up $794k, +8.4% YoY) to support multiple device fabrication vendors and new runs; company noted improved efficiency using AI-driven development and TCAD simulation to guide experiments.
Quarterly Operating Improvement
Q4 2025 non-GAAP net loss improved to $3.3M ($0.10/share) from $4.4M in Q3 2025 (a reduction of ~25%) and from $3.9M in Q4 2024 (improvement of ~15%), driven in part by reversal of bonus accrual.
Strategic Partnership with Equipment OEM
Announced a strategic partnership with a large equipment OEM to accelerate validation and potential adoption of MST in advanced-node manufacturing, leveraging the OEM's industry influence to facilitate customer trials.
Negative Updates
Very Low Revenue Base
Total revenue for 2025 was only $65,000 (consisting of NRE fees and MST CAD licensing), with only modest Q1 2026 revenue expected in the range of $50,000 to $100,000—indicating minimal near-term product revenue.
Sustained Net Losses and Rising GAAP Expense
GAAP net loss increased to $20.2M in 2025 from $18.4M in 2024 (increase of $1.8M, +9.8%). Non-GAAP net loss rose to $16.1M from $15.4M (+$0.7M, +4.5%). GAAP operating expenses increased ~8.3% to $20.9M.
Cash Decline and Cash Burn
Cash, cash equivalents and short-term investments fell to $19.2M at Dec 31, 2025 from $26.7M at year-end 2024 (decline of $7.5M, -28.1%). The company used $14.9M of cash in operating activities during 2025, raising concern about runway and financing needs.
Equity Dilution and Lower Post-Year-End Share Price
Issued ~1.6M shares in 2025 under ATM for net proceeds of ~$7.6M (avg $5.15/share) and sold an additional ~1.3M shares after year-end for ~$3.2M (avg $2.47/share), increasing dilution to 32.4M shares outstanding and reflecting weaker share price in follow-on sales.
Commercial Adoption and Timing Uncertainty
Despite technical validation, commercialization depends on customer adoption and integration (especially for GAA), which can be lengthy and complex; customer test cycles typically take 6-9 months and licensing/commercial deals remain prospective rather than recognized revenue.
Increased 2026 Operating Expense Outlook and Bonus Accruals
2026 non-GAAP operating expense guidance is ~$18.5M (a 17% increase 'on paper'); the company notes this is largely due to timing of executive bonus accruals and could be ~8% higher on a normalized basis—earning back withheld bonuses will require aggressive commercial milestones.
Setback with Previous Partner and Ongoing Dependency on Partnerships
Company referenced a prior setback with ST (STMicro) and remains reliant on strategic partners and large OEMs to drive trials and adoption; this dependency adds execution risk despite technical wins.
Company Guidance
Atomera gave narrow near‑term guidance and clear cost guidance: for Q1 2026 it expects revenue of $50,000–$100,000 from MST wafer shipments (no guidance beyond the quarter), and it forecasts 2026 non‑GAAP operating expenses of about $18.5 million (a reported 17% increase versus 2025’s $15.9M, or roughly an 8% increase when normalized for the timing of the executive bonus accrual); management also noted the $669,000 of 2025 executive bonus withheld may be paid in 2026 if aggressive commercial milestones are met. Key year‑end metrics discussed were $19.2M in cash, cash equivalents and short‑term investments (vs. $26.7M at 12/31/2024), $14.9M cash used in operating activities in 2025 ($3.2M in Q4), 2025 non‑GAAP net loss of $16.1M ($0.52/share) and Q4 non‑GAAP net loss of $3.3M ($0.10/share), 32.4M shares outstanding, ~1.6M shares sold under the 2025 ATM for ~$7.6M net (avg $5.15), plus a post‑year‑end sale of ~1.3M shares for ~$3.2M net (avg $2.47).

Atomera Financial Statement Overview

Summary
Overall financials indicate a business that is not yet self-sustaining: revenue remains extremely small and volatile (2025 revenue ~$0.07M) with deeply negative profitability (EBIT loss ~$21.1M) and persistent cash burn (2025 operating cash flow about -$14.9M). Low leverage helps reduce balance-sheet risk, but equity has declined materially over time, reflecting ongoing losses.
Income Statement
9
Very Negative
Revenue is highly volatile and remains extremely small relative to the cost base (2025 annual revenue of ~$0.07M vs. EBIT loss of ~$21.1M). While 2025 shows a large percentage revenue increase, profitability deteriorated sharply with negative gross profit and deeply negative margins, indicating weak operating leverage and limited near-term path to break-even based on the provided results.
Balance Sheet
56
Neutral
Leverage is low (debt-to-equity ~0.08–0.24 across the period; ~0.11 in 2025), which reduces balance-sheet risk. However, equity has trended down meaningfully (from ~$37.3M in 2020 to ~$18.4M in 2025) and returns on equity are consistently very negative, reflecting ongoing losses that continue to erode the capital base.
Cash Flow
18
Very Negative
Cash burn is persistent and sizable, with operating cash flow negative every year (about -$12M to -$15M, including -$14.9M in 2025) and free cash flow also consistently negative. Free cash flow broadly tracks net losses (roughly 1x), suggesting losses are translating into real cash outflows and increasing the likelihood of future funding needs if conditions don’t improve.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue65.00K135.00K550.00K382.00K400.00K
Gross Profit-304.00K12.00K522.00K301.00K400.00K
EBITDA-20.07M-16.94M-18.16M-15.68M-14.73M
Net Income-20.17M-18.43M-19.79M-17.36M-15.71M
Balance Sheet
Total Assets21.09M29.12M24.03M26.73M36.06M
Cash, Cash Equivalents and Short-Term Investments19.21M26.77M19.53M21.18M28.70M
Total Debt1.99M1.98M3.64M4.88M6.54M
Total Liabilities2.71M4.05M5.86M6.42M7.68M
Stockholders Equity18.38M25.08M18.17M20.31M28.38M
Cash Flow
Free Cash Flow-14.87M-13.25M-14.59M-12.54M-12.55M
Operating Cash Flow-14.87M-13.24M-14.56M-12.50M-12.44M
Investing Cash Flow951.00K6.08M-6.75M-39.00K-109.00K
Financing Cash Flow7.35M20.34M12.71M5.02M3.31M

Atomera Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.24
Price Trends
50DMA
3.15
Positive
100DMA
3.09
Positive
200DMA
3.93
Positive
Market Momentum
MACD
0.79
Negative
RSI
58.18
Neutral
STOCH
34.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOM, the sentiment is Positive. The current price of 5.24 is above the 20-day moving average (MA) of 4.22, above the 50-day MA of 3.15, and above the 200-day MA of 3.93, indicating a bullish trend. The MACD of 0.79 indicates Negative momentum. The RSI at 58.18 is Neutral, neither overbought nor oversold. The STOCH value of 34.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATOM.

Atomera Risk Analysis

Atomera disclosed 25 risk factors in its most recent earnings report. Atomera reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Atomera Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
57
Neutral
$260.34M-455.60-0.91%-0.41%-134.49%
56
Neutral
$202.27M-6.57-44.72%-21.59%-254.69%
55
Neutral
$202.77M-8.00-116.86%-94.26%3.20%
52
Neutral
$2.56B-94.88-9.12%-4.54%-119.39%
46
Neutral
$50.55M-120.36%2.80%
42
Neutral
$78.63M-8.72-24.81%-42.77%83.21%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATOM
Atomera
5.24
-0.08
-1.50%
ASYS
Amtech Systems
14.04
9.08
183.06%
AXTI
AXT
46.32
44.77
2888.39%
SQNS
Sequans Communications S A
3.16
-19.24
-85.89%
MRAM
Everspin Technologies
11.39
5.93
108.61%
WKEY
WISeKey International Holding
7.02
3.33
90.24%

Atomera Corporate Events

Business Operations and StrategyPrivate Placements and Financing
Atomera Announces $25 Million Registered Direct Offering
Positive
Feb 24, 2026

On February 23, 2026, Atomera Incorporated entered into a securities purchase agreement with institutional investors for a registered direct offering of 5,000,000 common shares at $5.00 each, for expected gross proceeds of $25 million. The deal, conducted under an effective shelf registration, was scheduled to close on or about February 24, 2026, with Craig-Hallum Capital Group acting as sole placement agent.

Atomera plans to use the net proceeds for working capital and general corporate purposes, strengthening its financial flexibility as it advances its semiconductor materials licensing business. The company, its executives and directors agreed to 90-day restrictions on additional stock issuances and insider share disposals, aligning stakeholders during the immediate post-offering period.

The most recent analyst rating on (ATOM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atomera stock, see the ATOM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 25, 2026